Table 5 Clinical and laboratory data of patients with systemic sclerosis, depending on soluble fractalkine concentrations

 Age, years, median [IQR]

55.06 [50.94–72.84]

62.52 [52.8–71.33]

0.56

 Duration, years, median [IQR]

5.5 [3–12.75]

8 [3–12.5]

0.8933

 Pitting scars or skin ulcers, n

11/16

14/25

0.41

 Pulmonary fibrosis, n

3/16

3/22

<0.0001***

 FVC, %, median [IQR]

98.5[85.75–113.3]

95.9 [82–111.3]

0.558

 DLCO/VA, %, median [IQR]

62 [53–76]

75 [63.5–81.45]

0.0445*

 Oesophagus, n

13/16

13/25

0.0579

 Telangiectasia, n

9/16

20/25

0.1030

 mRSS, median [IQR]

11.5 [5.25–23]

10 [5–16]

0.6166

 Pulmonary arterial pressure, mmHg, median [IQR]

27 [21.25–34]

25 [20–31]

0.32

 Severity grades 0, 1 and 2, n

4/16

15/25

0.0284*

 Severity grades 3 and 4, n

12/16

10/25

0.0284*

 Anti-topoisomerase I antibody, n

6/16

13/25

0.3638

 Anti-centromere antibody, n

7/16

12/25

0.79